TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02762929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011B
Description: HTX-011B (bupivacaine/meloxicam), via injection or instillation.
Study: NCT03802279

Intervention type: OTHER
Intervention: Effort test
Description: Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated.

Intervention type: OTHER
Intervention: Effort test
Description: Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated.

Intervention type: OTHER
Intervention: Functional tests on fibroblasts
Description: Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.

Intervention type: OTHER
Intervention: Functional tests on fibroblasts
Description: Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
Study: NCT02762929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-002
Description: HTX-002, via injection.
Study: NCT02953873

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil
Description: ≥500mg twice a day
Study: NCT04632771

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)

Intervention type: OTHER
Intervention: N/A (observational study)
Description: N/A (observational study)
Study: NCT02610686

Intervention type: DRUG
Group type: OTHER
Intervention: Chloroquine
Description: efficacy of chloroquine for the treatment of Plasmodium vivax infections
Study: NCT02556606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
Study: NCT00362648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
Description: 2.0 mL oral dose of RotaTeq™. 14 week treatment period
Study: NCT02556606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: single 40 min infusion of MID 0.03mg/Kg
Study: NCT02762929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCI, via injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-009
Description: HTX-009, via injection.
Study: NCT01117896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest compression on adult and pedi manikins
Description: Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
Study: NCT00514670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer & quaternary ammonium wipes
Study: NCT01117896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of stepstool during chest compressions
Description: In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
Study: NCT01773707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTLA4-Ig (Abatacept)
Description: Given as 30 minute IV infusion
Study: NCT01432067

Intervention type: OTHER
Group type: OTHER
Intervention: Adapted physical activity
Description: Physical activity advices according to a program adapted to physical status of the patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Classic physical activities
Description: Daily physical activities based on a standard guide
Study: NCT01416636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treprostinil sodium
Study: NCT02953873

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: goal dose 5mg daily

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Sodium
Description: ≥360mg twice a day
Study: NCT03574818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab-Gemcitabine-Cisplatin
Description: * Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation to determine if patient is a candidate to proceeed with surgical resection or not
Description: Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
Study: NCT00078273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
Study: NCT02922231

Intervention type: BIOLOGICAL
Intervention: RIXUBIS
Description: Recombinant Factor IX (rFIX) for intravenous use
Study: NCT02355314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doppler-based renal
Description: Doppler-based renal : day 0 and day 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample and urine sample
Description: blood sample and urine sample : day 0 and day 3
Study: NCT02361801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal dobutamine protocol
Description: All patients will receive dobutamine at the cardiopulmonary bypass weaning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive dobutamine protocol
Description: Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
Study: NCT01595399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine
Description: Atropine 0.02 mg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an equivalent volume of normal saline to atropine IV
Study: NCT04141085

Intervention type: OTHER
Intervention: Endometrial biopsy
Description: All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer

Intervention type: OTHER
Intervention: Endometrial biopsy
Description: All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
Study: NCT02085798

Intervention type: OTHER
Intervention: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
Description: As described above

Intervention type: OTHER
Intervention: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
Description: As described above

Intervention type: OTHER
Intervention: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
Description: As described above
Study: NCT01699100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device
Description: Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
Study: NCT03429465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVO Cognitive Remediation Game
Description: EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
Study: NCT03041818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horseback riding therapy
Description: Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
Study: NCT01912469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study: NCT00526929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: 10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
Study: NCT00106613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK228 (romidepsin)
Description: Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT00362648

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Arm 2: Placebo. 14 week treatment period
Study: NCT03422276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Discharge Plan
Description: CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Transition Plan
Description: Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population.
Study: NCT04649151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Description: Sterile solution for injection
Study: NCT04399395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone/bupropion
Description: Approved drug for obesity treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle
Description: Lifestyle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: Lifestyle
Study: NCT03072264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body in Mind Training (BMT)
Description: Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Group
Description: Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
Study: NCT00397384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01217762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system
Study: NCT03237793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorosed Group
Description: A single episode of laser therapy with without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non Flourosed Group
Description: A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment.
Study: NCT04485559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT05031793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM
Description: TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western medicine
Description: Western medicine include nasal spray steroid, oral antihistamine
Study: NCT00354172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity.
Study: NCT05031793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: Western medicine include nasal spray steroid, oral antihistamine
Study: NCT03308006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
Study: NCT02322437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home treatment
Description: Patients are treated at home whenever possible and appropriate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Patients are treated at a mental hospital
Study: NCT00354172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9 /L).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation (UCBT)
Description: The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
Study: NCT01387841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: Postures,relaxation techniques

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jacobsons PMRT group
Description: jacobsons Progressive muscle relaxation training involving 16 muscle groups
Study: NCT04282252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V. SOLUTIONS
Description: All i.v. fluids used in an Intensive Care Unit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V. SOLUTIONS
Description: All i.v. fluids used in an Intensive Care Unit.